|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2009-7-14
|
|
pubmed:abstractText |
To investigate the safety, tolerability, pharmacokinetic and pharmacodynamic properties of multiple oral doses of the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin (BI 1356) in patients with type 2 diabetes mellitus.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1463-1326
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
786-94
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19476474-Administration, Oral,
pubmed-meshheading:19476474-Adult,
pubmed-meshheading:19476474-Area Under Curve,
pubmed-meshheading:19476474-Diabetes Mellitus, Type 2,
pubmed-meshheading:19476474-Dipeptidyl Peptidase 4,
pubmed-meshheading:19476474-Dipeptidyl-Peptidase IV Inhibitors,
pubmed-meshheading:19476474-Dose-Response Relationship, Drug,
pubmed-meshheading:19476474-Double-Blind Method,
pubmed-meshheading:19476474-Half-Life,
pubmed-meshheading:19476474-Humans,
pubmed-meshheading:19476474-Male,
pubmed-meshheading:19476474-Metabolic Clearance Rate,
pubmed-meshheading:19476474-Middle Aged,
pubmed-meshheading:19476474-Purines,
pubmed-meshheading:19476474-Quinazolines,
pubmed-meshheading:19476474-Young Adult
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.
|
|
pubmed:affiliation |
Profil Institut für Stoffwechselforschung GmbH, Hellersbergstrasse, Neuss, Germany.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Multicenter Study
|
